Stocks Actavis Inc

More

  • UPDATE 1-Allergan says in talks on merger with Pfizer Thursday, 29 Oct 2015 | 9:43 AM ET

    Oct 29- Botox maker Allergan Plc on Thursday said it was in preliminary, friendly talks with Pfizer Inc on a potential merger, a deal that would create the world's largest drugmaker. Ireland- based Allergan said there was no certainty the talks would lead to a deal, and did not discuss the terms that might lead to a tie-up with Pfizer. Pfizer Chief Executive Officer...

  • Oct 29- Allergan Plc's shares soared as much as 16 percent in premarket trading on Thursday, a day after media reports that Pfizer Inc had held early talks with the Botox-maker about a deal that would create the world's biggest drugmaker. A combination of Dublin- based Allergan with New York- based Pfizer would create a $330- billion pharma giant and extend an...

  • Oct 29- U.S. stock index futures were lower on Thursday, a day after the Federal Reserve revived expectations of an increase in interest rates in December. *The Fed's hawkish tone came as a surprise, prompting an increase in the odds of a December hike to 43 percent from the 38 percent minutes before the release of the statement, according to the CME Group's FedWatch...

  • Pfizer said to be in talks with Allergan Thursday, 29 Oct 2015 | 7:07 AM ET
    Pfizer headquarters in New York.

    Pfizer has held early talks with Allergan to discuss what could be the biggest takeover deal this year, according to media reports.

  • *Pfizer and Allergan decline to comment. A bid for Allergan, which has a market value of $113 billion, would be Pfizer's second recent attempt to acquire a big rival, following its unsuccessful courtship last year of Anglo-Swedish pharmaceuticals group AstraZeneca Plc. Combining Allergan and Pfizer, which is worth $219 billion, would create the world's largest...

  • Oct 28- Pharmaceutical giant Pfizer Inc recently approached Botox-maker Allergan Plc to discuss what could be the biggest takeover deal this year, the Wall Street Journal said on Wednesday, citing people familiar with the matter. A bid for Allergan, which has a market value of $113 billion, would be Pfizer's second attempt to acquire a European rival, following...

  • Oct 28- Drugmakers Pfizer Inc and Allergan Plc are considering combining in what could be the biggest merger in the healthcare industry in already busy year, the Wall Street Journal said on Wednesday. Pfizer recently approached botox-maker Allergan about a deal, the Journal said, citing people familiar with the matter. Both Pfizer and Allergan's shares were...

  • UPDATE 1-Pfizer, Allergan considering a combination - WSJ Wednesday, 28 Oct 2015 | 8:59 PM ET

    Oct 28- Pfizer Inc and Allergan Plc are considering combining, the Wall Street Journal said on Wednesday. Pfizer recently approached Allergan about a deal, the Journal said, citing people familiar with the matter. Pfizer was not immediately available for comment, while Allergan declined to comment.

  • Oct 28- Pfizer Inc and Allergan Plc are considering a combination, CNBC tweeted on Wednesday, citing Dow Jones.

  • Valeant woes underline problems for pharma Friday, 23 Oct 2015 | 2:31 PM ET

    NEW YORK, Oct 23- The pharma sector needs more than medicine to get over its latest malaise. But the wheels began to come off the wagon the following month, when Martin Shkreli, a former hedge fund executive and the founder of Turing Pharmaceuticals, jacked up the price of an Aids drug Turing had acquired from US $13.50 per pill to US $750. Hillary Clinton, making a White...

  • The firm's woes mean a likely loss of lucrative business for JPMorgan Chase& Co, Goldman Sachs Group Inc and other major investment banks. Since 2012, only General Electric Co, Allergan Plc, AT&T Inc and Dell Inc have paid more than Valeant in fees to Wall Street, according to data from Freeman and Co, a consulting firm. JPMorgan and Goldman Sachs have been top...

  • Valeant slump poses big threat to small hedge funds Thursday, 22 Oct 2015 | 7:46 PM ET

    BOSTON/ NEW YORK, Oct 22- Valeant Pharmaceuticals' market slide has hurt the returns of several large U.S. hedge funds, but for smaller players with outsized bets on the drug company the fallout could be far more painful, according to industry watchers. They include Tiger Ratan Capital Management, Marble Arch Investments, and Brave Warrior Advisors, according to...

  • LOS ANGELES, Oct 21- Investor concerns over accounting practices at Valeant Pharmaceuticals International Inc have put a spotlight on the little-known and fast-growing specialty pharmacy industry. Shares of Valeant fell 19 percent on Wednesday after influential short-seller Citron Research accused the company of using specialty pharmacies, through a...

  • US STOCKS-Wall St declines; Valeant, healthcare weigh Wednesday, 21 Oct 2015 | 6:33 PM ET

    Oct 21- U.S. stocks fell on Wednesday as a sharp drop in Valeant Pharmaceuticals hit the healthcare space, while the energy sector dropped along with oil prices. Valeant Pharmaceuticals' U.S.-listed shares plunged to an intraday low of $88.50 on record volume after a short-seller accused the company of using specialty pharmacies to inflate its revenue.

  • US STOCKS-Wall St falls; Valeant, healthcare drop Wednesday, 21 Oct 2015 | 4:57 PM ET

    *Valeant sinks after Citron report, drags Allergan. Shares of Allergan, which has a business model similar to that of Valeant, was down 1.7 percent at $259, cutting earlier losses after the company said nearly all of its drugs are being distributed through traditional wholesale and retail channels. Also in the healthcare sector, insurers Aetna, Humana, Anthem and...

  • US STOCKS-S&P 500, Nasdaq dip with healthcare, Yahoo Wednesday, 21 Oct 2015 | 3:39 PM ET

    *Valeant sinks after Citron report, drags Allergan, Endo. Oct 21- The S&P 500 and Nasdaq slipped in choppy trading late Wednesday afternoon as insurers and other big healthcare names dropped and Yahoo shares fell following disappointing results. Shares of Allergan, which has a business model similar to that of Valeant, fell 4.6 percent to $251.37, though the...

  • NEW YORK, Oct 21- Valeant Pharmaceuticals International Inc plunged as much as 40 percent after an influential short-seller accused the company of using specialty pharmacies to inflate its revenue, an allegation that the drugmaker denied. Citron Research, a short-selling firm run by Andrew Left, alleged that Valeant's previously undisclosed ties to...

  • *Valeant sinks after Citron report, drags Allergan, Endo. Oct 21- Wall Street was little changed in early afternoon trading on Wednesday as gains by General Motors and technology stocks were limited by a slide in healthcare stocks. Allergan fell 4.6 percent to $251.37 and Endo International slumped nearly 13 percent to $54.98, weighing the most on the S&P 500 and...

  • Allergan clarifies on drug distribution practices Wednesday, 21 Oct 2015 | 12:20 PM ET

    Oct 21- Drugmaker Allergan Plc said on Wednesday that nearly all of its drugs are being distributed through traditional wholesale and retail channels. Allergan's clarification comes two days after a New York Times report said drugmakers were using specialty pharmacy distributors to work around barriers to increase drug prices. The company also said on...

  • SYDNEY, Oct 21- Asian shares eked out cautious gains on Wednesday as concerns about corporate earnings hobbled Wall Street while investors counted down to the European Central Bank's policy meeting later in the week. MSCI's broadest index of Asia-Pacific shares outside Japan was a fraction firmer. The S&P healthcare sector shed 1.5 percent, dragged by...